Genentech Xanelim, Biogen Amevive Pivotal Trial Data In Psoriasis Presented
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A second course of treatment with Genentech and Xoma’s monoclonal antibody Xanelim (efalizumab) resulted in an additional 20% of psoriasis patients achieving the primary efficacy endpoint, according to data from a pivotal trial presented June 21 at the 2nd Joint Meeting of the International Psoriasis Symposium and European Congress on Psoriasis.